Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-dose Henlius trastuzumab in neoadjuvant HER2-positive breast cancer
ChiCTR2200064722Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Miller-Payne grade and MRI report. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200064722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064722.